ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 9,520 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $65.40, for a total transaction of $622,608.00. Following the sale, the chief operating officer now owns 809,852 shares of the company’s stock, valued at $52,964,320.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Muthusamy Shanmugam also recently made the following trade(s):

• On Monday, April 15th, Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.33, for a total value of $491,770.62.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total value of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total value of $659,577.55.
• On Monday, January 22nd, Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.95, for a total value of $318,467.40.
• On Thursday, January 18th, Muthusamy Shanmugam sold 9,784 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.30, for a total value of $541,055.20.

ANI Pharmaceuticals Trading Down 1.4 %

Shares of ANIP opened at $64.58 on Friday. ANI Pharmaceuticals, Inc. has a fifty-two week low of $36.99 and a fifty-two week high of $70.81. The stock has a fifty day moving average of $64.77 and a two-hundred day moving average of $58.57. The company has a market capitalization of $1.36 billion, a PE ratio of 76.88 and a beta of 0.79. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.81 and a current ratio of 3.57.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The company had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current year.

Analyst Ratings Changes

ANIP has been the subject of several research reports. Guggenheim lifted their price objective on ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Capital One Financial assumed coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price target for the company. Truist Financial boosted their price target on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, HC Wainwright boosted their price target on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a report on Monday, March 4th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $80.00.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ANIP. Swiss National Bank boosted its position in ANI Pharmaceuticals by 7.1% during the 1st quarter. Swiss National Bank now owns 27,000 shares of the specialty pharmaceutical company’s stock worth $759,000 after purchasing an additional 1,800 shares during the period. Citigroup Inc. boosted its position in ANI Pharmaceuticals by 44.9% during the 1st quarter. Citigroup Inc. now owns 12,516 shares of the specialty pharmaceutical company’s stock worth $352,000 after purchasing an additional 3,881 shares during the period. PNC Financial Services Group Inc. boosted its position in ANI Pharmaceuticals by 15.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,828 shares of the specialty pharmaceutical company’s stock valued at $108,000 after buying an additional 512 shares during the last quarter. MetLife Investment Management LLC boosted its position in ANI Pharmaceuticals by 57.0% in the 1st quarter. MetLife Investment Management LLC now owns 5,858 shares of the specialty pharmaceutical company’s stock valued at $165,000 after buying an additional 2,127 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in ANI Pharmaceuticals by 4.4% in the 1st quarter. Rhumbline Advisers now owns 25,916 shares of the specialty pharmaceutical company’s stock valued at $728,000 after buying an additional 1,096 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.